Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes in North India: A 12-month prospective study in real-world setting

被引:15
作者
Ghosh, Amerta [1 ]
Gupta, Ritesh [1 ,2 ]
Singh, Padam [1 ]
Dutta, Abhinav [1 ]
Misra, Anoop [1 ,2 ]
机构
[1] Fortis C DOC Hosp Diabet Metab Dis & Endocrinol, New Delhi, India
[2] Natl Diabet Obes & Cholesterol Fdn, New Delhi, India
关键词
INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; CANAGLIFLOZIN; METFORMIN; EFFICACY; SAFETY; SITAGLIPTIN; EMPAGLIFLOZIN; DAPAGLIFLOZIN; ASSOCIATION;
D O I
10.1111/ijcp.13237
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly being used in India. However, there is paucity of real-world clinical data of SGLT2 inhibitors. We aim to provide real-world experience regarding efficacy and safety of these drugs in Asian Indian patients with type 2 diabetes mellitus. Methodology: We enrolled patients with type 2 diabetes mellitus who were given SGLT2 inhibitors on top of other antidiabetes medication. After initial work up, patients were followed up to 12 months. Measurements included weight, body mass index, blood pressure, HbA1C, fasting and postprandial blood glucose, lipids, urinary microalbumin, etc. Results: Out of 1297 patients; 310 patients completed 12-month follow-up. Mean difference followed by percentage reduction of various parameters at 12 months was as follows; weight reduction (kg), -3.45 (95% CI, -2.9-4.0), 4.5; body mass index, (kg/m(2)), -1.26 (95% CI, -1.0-1.5), 4.4; HbA1c (%), -1.8 (95% CI, -0.2-3.40), 19; fasting blood glucose (mg/dL), -35.7 (95% CI, -27.2-44.1), 25.3; postprandial blood glucose (mg/dL), -54.7 (95% CI, -39.8-69.7), 25.3; systolic blood pressure (mm Hg), -8.25 (95% CI, -5.8-10.7), 5.2; diastolic blood pressure (mm Hg), -2.33 (95% CI, -1.0-3.6), 1.1; and serum triglycerides (mg/dL), -25.77 (95% CI, -9.1-42.5), 10.5. Of note, 41.9% and 10.6% of patients showed more than 5 and 10% decrease in body weight, respectively. Adverse drug reactions were seen in 22.8% patients and 41 (3.2%) patients stopped SGLT2 inhibitors because of various reasons. Importantly, five patients had severe urinary tract infection, one patient developed acute kidney injury because of rapid rise in creatinine, three developed slow rise in creatinine and one patient developed acute pyelonephritis. Ketosis was seen in 10 patients of whom one developed severe ketoacidosis. We did not record severe hypoglycaemia, lower extremity amputation, stroke, or bone fractures in this cohort.
引用
收藏
页数:9
相关论文
共 27 条
  • [21] A Proposed India-Specific Algorithm for Management of Type 2 Diabetes
    Saboo, Banshi
    Misra, Anoop
    Mohan, Viswanathan
    Saboo, Banshi
    Unnikrishnan, Ranjit
    Shrivastava, Usha
    Joshi, Shashank
    Bajaj, Sarita
    Banerjee, Samar
    Das, A. K.
    Deshpande, Neeta
    Gupta, Arvind
    Gupta, Sunil
    Joshi, Shashank
    Jayakumar, R. V.
    Kesavadev, Jothydev
    Maheshwari, Anuj
    Misra, Anoop
    Mohan, V.
    Sahay, Rakesh
    Saboo, Banshi
    Sadikot, S. M.
    Shrivastava, Usha
    Shukla, Rishi
    Unnikrishnan, Ranjit
    Viswanathan, Vijay
    Wander, G. S.
    Comm, Extended
    Aravind, S. R.
    Bhansali, Anil
    Bhoraskar, Anil
    Chandalia, H. B.
    Chowdhury, Subhankar
    Kalra, Sanjay
    Kumar, Ajay
    Madhu, S. V.
    Mittal, Ambrish
    Prasannakumar, K. M.
    Ramachandran, A.
    Sethi, Bipin
    Tandon, Nikhil
    Yajnik, C. S.
    Zargar, A. H.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 (06) : 346 - 350
  • [22] Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
    Schernthaner, Guntram
    Gross, Jorge L.
    Rosenstock, Julio
    Guarisco, Michael
    Fu, Min
    Yee, Jacqueline
    Kawaguchi, Masato
    Canovatchel, William
    Meininger, Gary
    [J]. DIABETES CARE, 2013, 36 (09) : 2508 - 2515
  • [23] Sosale Bhavana, 2016, J Assoc Physicians India, V64, P40
  • [24] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
    Strojek, K.
    Yoon, K. H.
    Hruba, V.
    Elze, M.
    Langkilde, A. M.
    Parikh, S.
    [J]. DIABETES OBESITY & METABOLISM, 2011, 13 (10) : 928 - 938
  • [25] US FDA, 2015, DRUG SAF COMM FDA ST
  • [26] Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
    Vasilakou, Despoina
    Karagiannis, Thomas
    Athanasiadou, Eleni
    Mainou, Maria
    Liakos, Aris
    Bekiari, Eleni
    Sarigianni, Maria
    Matthews, David R.
    Tsapas, Apostolos
    [J]. ANNALS OF INTERNAL MEDICINE, 2013, 159 (04) : 262 - +
  • [27] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) : 2117 - 2128